Major Concomitant use of hydromorphone with other central nervous system CNS depressants, such as other opiate agonists, can potentiate the effects of hydromorphone and may lead to additive CNS or respiratory depression, profound sedation, or coma. Prior to concurrent use of hydromorphone in patients taking a CNS depressant, assess the level of tolerance to CNS depression that has developed, the duration of use, and the patient's overall response to treatment.
Moderate Concomitant use of iloperidone with other centrally-acting medications such as opiate agonists, may increase both the frequency and the intensity of adverse effects including drowsiness, sedation, and dizziness.
Moderate Imatinib is a potent inhibitor of cytochrome P 2D6 and may increase concentrations of other drugs metabolized by this enzyme including oxycodone. Moderate Concomitant use of oxycodone with indinavir may increase oxycodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.
Discontinuation of indinavir could decrease oxycodone plasma concentrations, decrease opioid efficacy, and potentially lead to a withdrawal syndrome in those with physical dependence to oxycodone. If indinavir is discontinued, monitor the patient carefully and consider increasing the opioid dosage if appropriate.
Moderate Coadministration of isavuconazonium, a CYP3A4 inhibitor and substrate, and oxycodone, a CYP3A4 substrate, may increase oxycodone plasma concentrations and increase or prolong related toxicities including potentially fatal respiratory depression. Moderate Concomitant use of oxycodone with isoniazid may increase oxycodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.
Discontinuation of isoniazid could decrease oxycodone plasma concentrations, decrease opioid efficacy, and potentially lead to a withdrawal syndrome in those with physical dependence to oxycodone.
If isoniazid is discontinued, monitor the patient carefully and consider increasing the opioid dosage if appropriate. Moderate Coadministration of oxycodone, a CYP3A4 substrate, with rifampin, a CYP3A4 inducer, may cause increased clearance of oxycodone, which could result in lack of efficacy or the development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone. An inducer of CYP2D6, such as rifampin, could convert a greater percentage of the dose to oxymorphone, which has analgesic activity.
In the presence of a CYP2D6 inducer, more oxycodone could be converted to oxymorphone. Also, conversion of oxycodone to noroxycodone may be enhanced. Noroxycodone is reported to be a considerably weaker analgesic than oxycodone. Monitor the patient for excessive adverse effects of oxycodone or reduced efficacy of oxycodone. A lower or higher oxycodone dose may be needed if used with rifampin.
Moderate Concomitant use of oxycodone with itraconazole may increase oxycodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death. Discontinuation of itraconazole could decrease oxycodone plasma concentrations, decrease opioid efficacy, and potentially lead to a withdrawal syndrome in those with physical dependence to oxycodone. If itraconazole is discontinued, monitor the patient carefully and consider increasing the opioid dosage if appropriate.
Minor Use caution when administering ivacaftor and oxycodone concurrently. Co-administration of ivacaftor with CYP3A substrates, such as oxycodone, can theoretically increase oxycodone exposure leading to increased or prolonged therapeutic effects and adverse events; however, the clinical impact of this has not yet been determined. Concomitant administration of a CYP3A4 inhibitor, such as ketoconazole, may cause an increase in oxycodone plasma concentrations, which could increase or prolong adverse effects and may cause potentially fatal respiratory depression.
Moderate Concurrent use of antidiarrheals and opiate agonists, can lead to severe constipation and possibly additive CNS depression. Major Coadministration of lapatinib, a CYP3A4 inhibitor, and oxycodone, a CYP3A4 substrate, may increase oxycodone plasma concentrations and increase or prolong related toxicities including potentially fatal respiratory depression. Moderate Concomitant use of oxycodone with letermovir may increase oxycodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.
In patients also receiving cyclosporine, the magnitude of this interaction may be amplified. Discontinuation of letermovir could decrease oxycodone plasma concentrations, decrease opioid efficacy, and potentially lead to a withdrawal syndrome in those with physical dependence to oxycodone. If letermovir is discontinued, monitor the patient carefully and consider increasing the opioid dosage if appropriate.
Moderate Lincosamides, which have been shown to exhibit neuromuscular blocking action, can enhance the effects of opiate agonists if used concomitantly, enhancing respiratory depressant effects. They should be used together with caution and the patient carefully monitored. Major Serotonin syndrome can occur during concomitant use of opiate agonists with serotonergic drugs, such as linezolid.
Moderate Monitor for excessive hypotension and sedation during coadministration of lofexidine and oxycodone. Lofexidine can potentiate the effects of CNS depressants. Concurrent use of selected antidiarrheals e.
Moderate Loxapine can potentiate the actions of other CNS depressants such as opiate agonists. Moderate Lumacaftor; ivacaftor may induce the metabolism of oxycodone, which could result in lack of therapeutic efficacy or the development of an abstinence syndrome in patients who are physically dependent on opioids.
If coadministration is necessary, monitor the patient closely at frequent intervals for appropriate pain control and signs of opioid withdrawal. Consider oxycodone dosage adjustments until stable drug effects are achieved. If lumacaftor; ivacaftor is subsequently discontinued, oxycodone plasma concentrations will increase. Monitor the patient closely at frequent intervals for oversedation and respiratory depression and reduce the oxycodone dosage as appropriate.
Moderate Due to the CNS effects of lurasidone, caution should be used when lurasidone is given in combination with other centrally acting medications such as opiate agonists. Minor Because of the CNS-depressant effects of magnesium sulfate, additive central-depressant effects can occur following concurrent administration with CNS depressants such as opiate agonists.
Caution should be exercised when using these agents concurrently. Moderate Concomitant use of oxycodone with other CNS depressants, such as maprotiline, can lead to additive respiratory depression, hypotension, profound sedation, or coma. Prior to concurrent use of oxycodone in patients taking maprotiline, assess the level of tolerance to CNS depression that has developed, the duration of use, and the patient's overall response to treatment.
Also consider using a lower maprotiline dose. Major Concomitant use of methadone with another CNS depressant, such as oxycodone, can lead to additive respiratory depression, hypotension, profound sedation, or coma. Prior to concurrent use of methadone in patients taking a CNS depressant, assess the level of tolerance to CNS depression that has developed, the duration of use, and the patient's overall response to treatment.
Methadone should be used with caution and in reduced dosages if used concurrently with a CNS depressant; in opioid-naive adults, use an initial methadone dose of 2. Also, consider a using a lower dose of the CNS depressant; use an initial dose of oxycodone at one-third to one-half the usual dosage.
If a decision is made to start treatment with acetaminophen; oxycodone extended-release tabIets, start with 1 tablet PO every 12 hours.
Moderate Opiate agonists antagonize GI motility and can decrease the gastroprokinetic effects of metoclopramide. Other drugs that may also cause drowsiness, such as opiate agonists, should be used with caution. Moderate The concomitant administration of metyrosine with opiate agonists can result in additive sedative effects. Moderate Concomitant use of oxycodone with mifepristone may increase oxycodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.
Discontinuation of mifepristone could decrease oxycodone plasma concentrations, decrease opioid efficacy, and potentially lead to a withdrawal syndrome in those with physical dependence to oxycodone. If mifepristone is discontinued, monitor the patient carefully and consider increasing the opioid dosage if appropriate. Minor Injectable minocycline contains magnesium sulfate heptahydrate. Because of the CNS-depressant effects of magnesium sulfate, additive central-depressant effects can occur following concurrent administration with CNS depressants such as opiate agonists.
Exposure of drugs partially metabolized by CYP2D6, such as oxycodone, may be increased when co-administered with mirabegron. Therefore, appropriate monitoring and dose adjustment may be necessary. Moderate Concomitant use of oxycodone with other CNS depressants, such as mirtazapine, can lead to additive respiratory depression, hypotension, profound sedation, or coma.
Prior to concurrent use of oxycodone in patients taking mirtazapine, assess the level of tolerance to CNS depression that has developed, the duration of use, and the patient's overall response to treatment.
Oxycodone should be used in reduced dosages if used concurrently with a CNS depressant; initiate oxycodone at one-third too one-half the usual dosage in patients that are concurrently receiving another CNS depressant.
Also consider using a lower mirtazapine dose. Major Use caution if mitotane and oxycodone are used concomitantly, and monitor for decreased efficacy of oxycodone, a possible change in dosage requirements, and possible development of an abstinence syndrome in a patient with physical dependence to oxycodone. Moderate Concomitant use of opiate agonists with other central nervous system CNS depressants, such as molindone, can potentiate the effects of the opiate and may lead to additive CNS or respiratory depression, profound sedation, or coma.
Initiate oxycodone at one-third to one-half the usual dosage in patients that are concurrently receiving another CNS depressant. Also consider using a lower dose of the CNS depressant. Advise patients against driving or performing other tasks requiring alertness until they know how the combination affects them. Prior to concurrent use, assess the level of tolerance to CNS depression that has developed and the patient's overall response to treatment.
For extended-release morphine products, start with the lowest possible dose of morphine i. Moderate Concomitant use of opiate agonists with other central nervous system CNS depressants, such as nabilone, can potentiate the effects of the opiate and may lead to additive CNS or respiratory depression, profound sedation, or coma.
Major Avoid the concomitant use of nalbuphine and opiate agonists, such as oxycodone. Nalbuphine may cause withdrawal symptoms in patients receiving chronic opiate agonists.
Concurrent use of nalbuphine with other opiate agonists can cause additive CNS, respiratory, and hypotensive effects. Moderate Concomitant use of oxycodone with other CNS depressants, such as nefazodone, can lead to additive respiratory depression, hypotension, profound sedation, or coma. Prior to concurrent use of oxycodone in patients taking nefazodone, assess the level of tolerance to CNS depression that has developed, the duration of use, and the patient's overall response to treatment.
Also, consider using a lower nefazodone dose. Major The potential for hypotension may be increased when coadministering nesiritide with opiate agonists. Moderate Concomitant use of oxycodone with netupitant may increase oxycodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.
Discontinuation of netupitant could decrease oxycodone plasma concentrations, decrease opioid efficacy, and potentially lead to a withdrawal syndrome in those with physical dependence to oxycodone. If netupitant is discontinued, monitor the patient carefully and consider increasing the opioid dosage if appropriate. Moderate Concomitant use of oxycodone with nicardipine may increase oxycodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.
Discontinuation of nicardipine could decrease oxycodone plasma concentrations, decrease opioid efficacy, and potentially lead to a withdrawal syndrome in those with physical dependence to oxycodone. If nicardipine is discontinued, monitor the patient carefully and consider increasing the opioid dosage if appropriate. Moderate Concomitant use of oxycodone with nilotinib may increase oxycodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.
Discontinuation of nilotinib could decrease oxycodone plasma concentrations, decrease opioid efficacy, and potentially lead to a withdrawal syndrome in those with physical dependence to oxycodone.
If nilotinib is discontinued, monitor the patient carefully and consider increasing the opioid dosage if appropriate. Minor Nitroglycerin can cause hypotension. This action may be additive with other agents that can cause hypotension such as opiate agonists. Patients should be monitored more closely for hypotension if nitroglycerin is used concurrently with opiate agonists.
Major Octreotide can cause additive constipation with opiate agonists such as oxycodone. Monitor patients during concomitant use. Also, coadministration of octreotide, a CYP3A4 inhibitor, and oxycodone, a CYP3A4 substrate, may increase oxycodone plasma concentrations and increase or prolong related toxicities including potentially fatal respiratory depression.
Plasma concentrations and efficacy of oxycodone may be reduced if these drugs are administered concurrently. If the extended-release oxymorphone tablets are used concurrently with a CNS depressant, it is recommended to use an initial dosage of 5 mg PO every 12 hours. If palbociclib is discontinued, consider an increased dose of oxycodone and monitor for signs of opioid withdrawal. Moderate Drugs that can cause CNS depression such as opiate agonists, if used concomitantly with paliperidone, can increase both the frequency and the intensity of adverse effects such as drowsiness, sedation, and dizziness.
Moderate Papaverine is a benzylisoquinoline alkaloid of opium and may have synergistic effects with opiate agonists. Concurrent use of papaverine with potent CNS depressants could lead to enhanced sedation.
Coadministration of pazopanib and oxycodone, a CYP3A4 substrate, may cause an increase in systemic concentrations of oxycodone. Use caution when administering these drugs concomitantly. In theory, concurrent use of a CYP2D6 inhibitor, such as peginterferon alfa-2b, may inhibit the conversion of oxycodone to oxymorphone.
In addition, concurrent use with a CYP2D6 inhibitor may increase the adverse effects of oxycodone. Close monitoring for pronounced opioid effects is advisable. Moderate In clinical trials, patients taking opiate agonists often required higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opiate agonists.
The mechanism of this interaction is unknown. The combination of perampanel particularly at high doses with ethanol has led to decreased mental alertness and ability to perform complex tasks such as driving , as well as increased levels of anger, confusion, and depression; similar reactions should be expected with concomitant use of other CNS depressants, such as opiate agonists.
Moderate Concomitant use of oxycodone with other CNS depressants, such as pimozide, can lead to additive respiratory depression, hypotension, profound sedation, or coma. Prior to concurrent use of oxycodone in patients taking pimozide, assess the level of tolerance to CNS depression that has developed, the duration of use, and the patient's overall response to treatment.
Also, consider using a lower pimozide dose. Moderate Concomitant use of oxycodone with posaconazole may increase oxycodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.
Discontinuation of posaconazole could decrease oxycodone plasma concentrations, decrease opioid efficacy, and potentially lead to a withdrawal syndrome in those with physical dependence to oxycodone. If posaconazole is discontinued, monitor the patient carefully and consider increasing the opioid dosage if appropriate. Moderate Concomitant use of oxycodone with other CNS depressants like pramipexole can lead to additive respiratory depression, hypotension, profound sedation, or coma.
Major Pramlintide slows gastric emptying and the rate of nutrient delivery to the small intestine. Medications with the potential to slow GI motility, such as opiate agonists, should be used with caution, if at all, with pramlintide until more data are available from the manufacturer.
Moderate Consider the use of a parenteral anti-platelet agent for patients with acute coronary syndrome who require concomitant opioid agonists.
Coadministration of opioid agonists with prasugrel delays and reduces the absorption of prasugrel's active metabolite due to slowed gastric emptying. Moderate Concomitant use of opiate agonists with other central nervous system CNS depressants can potentiate the effects of the opiate and may lead to additive CNS or respiratory depression, profound sedation, or coma. Examples of drugs associated with CNS depression include pregabalin. Moderate Opiate agonists may cause additive sedation or other CNS effects when given in combination with procarbazine.
Potent inhibitors of CYP2D6, such as propafenone, may potentially increase the effects of oxycodone; however, such blockade has not been shown to be of clinical significance during oxycodone treatment.
Moderate Concomitant use of oxycodone with other CNS depressants, such as quetiapine, can lead to additive respiratory depression, hypotension, profound sedation, or coma. Prior to concurrent use of oxycodone in patients taking quetiapine, assess the level of tolerance to CNS depression that has developed, the duration of use, and the patient's overall response to treatment. Also consider using a lower quetiapine dose.
Moderate Quinine inhibits CYP2D6 and may theoretically increase concentrations of other drugs metabolized by this enzyme. Caution is recommended when administering quinine with other CYP2D6 substrates that have a narrow therapeutic range or where large increases in serum concentrations may be associated with severe adverse reactions including oxycodone.
Although the concomitant use of ranolazine with oxycodone has not been studied, ranolazine may theoretically increase plasma concentrations of oxycodone, Studies of interactions with other CYP2D6 inhibitors and oxycodone have not demonstrated clinical significance.
Moderate Opiate agonists e. Moderate Use caution if coadministration of ribociclib with oxycodone is necessary, as the systemic exposure of oxycodone may be increased resulting in increase in treatment-related adverse reactions including sedation and respiratory depression; adjust the dose of oxycodone if necessary. Moderate Concomitant use of oxycodone with other CNS depressants, such as risperidone, can lead to additive respiratory depression, hypotension, profound sedation, or coma.
Prior to concurrent use of oxycodone in patients taking risperidone, assess the level of tolerance to CNS depression that has developed, the duration of use, and the patient's overall response to treatment. Also, consider using a lower risperidone dose. Major Use caution if oxycodone and rolapitant are used concurrently, and monitor for oxycodone-related adverse effects. Oxycodone is a CYP2D6 substrate where an increase in exposure may significantly increase adverse effects, and rolapitant is a moderate CYP2D6 inhibitor; the inhibitory effect of rolapitant is expected to persist beyond 28 days for an unknown duration.
Exposure to another CYP2D6 substrate, following a single dose of rolapitant increased about 3-fold on Days 8 and Day Moderate Concomitant use of opiate agonists with other central nervous system CNS depressants such as ropinirole can potentiate the effects of the opiate and may lead to additive CNS or respiratory depression, profound sedation, or coma. Moderate Consider a reduced dose of oxycodone with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary.
If rucaparib is discontinued, consider increasing the oxycodone dose until stable drug effects are achieved and monitor for evidence of opioid withdrawal. Coadministration can increase oxycodone exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of oxycodone. If rucaparib is discontinued, oxycodone plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to oxycodone.
Moderate Concomitant use of oxycodone with saquinavir may increase oxycodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.
Discontinuation of saquinavir could decrease oxycodone plasma concentrations, decrease opioid efficacy, and potentially lead to a withdrawal syndrome in those with physical dependence to oxycodone. If saquinavir is discontinued, monitor the patient carefully and consider increasing the opioid dosage if appropriate. Selective norepinephrine reuptake inhibitors: Moderate Prolonged erections have been reported in two patients taking sildenafil with dihydrocodeine.
Although more data are needed, use caution when prescribing opiate agonists and sildenafil concomitantly. Monitor patients for adverse effects of oxycodone, such as CNS and respiratory depression.
Major Additive CNS depressant effects may be possible when sodium oxybate is used concurrently with opiate agonists. Moderate Monitor patients for signs of urinary retention or reduced gastric motility when oxycodone is used concomitantly with an anticholinergic drug, such as solifenacin. Major Concomitant use of opioid agonists with suvorexant may cause respiratory depression, hypotension, profound sedation, and death.
Limit the use of opioid pain medications with suvorexant to only patients for whom alternative treatment options are inadequate. If an opioid agonist is initiated in a patient taking suvorexant, reduce initial dosage and titrate to clinical response.
If suvorexant is prescribed in a patient taking an opioid agonist, use a lower initial dose of suvorexant and titrate to clinical response. Major Additive CNS depressive effects are expected if tapentadol is used in conjunction with other CNS depressants, including other opiate agonists.
Severe hypotension, profound sedation, coma, or respiratory depression may occur. Prior to concurrent use of tapentadol in patients taking a CNS depressant, assess the level of tolerance to CNS depression that has developed, the duration of use, and the patient's overall response to treatment.
If the extended-release tapentadol tablets are used concurrently with a CNS depressant, it is recommended to use an initial tapentadol dose of 50 mg PO every 12 hours. Moderate Close clinical monitoring is advised when administering oxycodone with telaprevir due to an increased potential for oxycodone-related adverse events. If oxycodone dose adjustments are made, re-adjust the dose upon completion of telaprevir treatment.
Oxycodone is partially metabolized by the hepatic isoenzyme CYP3A4; telaprevir inhibits this isoenzyme. Major Coadministration of telithromycin and oxycodone may result in increased oxycodone plasma concentrations and a higher risk for adverse or prolonged effects, such as potentially fatal respiratory depression.
Moderate Use caution if coadministration of telotristat ethyl and oxycodone is necessary, as the systemic exposure of oxycodone may be decreased resulting in reduced efficacy and may lead to opioid withdrawal symptoms in patients physically dependent on oxycodone. If these drugs are used together, monitor patients for suboptimal efficacy of oxycodone or for signs or symptoms of opioid withdrawal; consider increasing the dose of oxycodone if necessary.
If telotristat ethyl is discontinued, oxycodone exposure may increase; monitor patients for respiratory depression and sedation and consider a oxycodone dose reduction. Potent inhibitors of CYP2D6, such as terbinafine, may potentially increase the effects of oxycodone; however, such blockade has not been shown to be of clinical significance during oxycodone treatment. Moderate Additive effects are possible when tetrabenazine is combined with other drugs that cause CNS depression.
Concurrent use of tetrabenazine and drugs that can cause CNS depression, such as opiate agonists, can increase both the frequency and the intensity of adverse effects such as drowsiness, sedation, dizziness, and orthostatic hypotension. Major Due to the central nervous system depression potential of local anesthetics, they should be used with caution with other agents that can cause respiratory depression, such as opiate agonists.
Restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. After each local anesthetic injection, careful and constant monitoring of ventilation adequacy, cardiovascular vital signs, and the patient's state of consciousness is advised. Major Avoid the concomitant use of thalidomide with opiate agonists; antihistamines; antipsychotics; anxiolytics, sedatives, and hypnotics; and other central nervous system depressants due to the potential for additive sedative effects.
Moderate Thiothixene can potentiate the CNS-depressant action of other drugs such as opiate agonists. Caution should be exercised during simultaneous use of these agents due to potential excessive CNS effects or additive hypotension. Coadministration of opioid agonists with ticagrelor delays and reduces the absorption of ticagrelor and its active metabolite due to slowed gastric emptying.
Moderate Concomitant use of oxycodone with tipranavir may increase oxycodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death. Discontinuation of tipranavir could decrease oxycodone plasma concentrations, decrease opioid efficacy, and potentially lead to a withdrawal syndrome in those with physical dependence to oxycodone.
If tipranavir is discontinued, monitor the patient carefully and consider increasing the opioid dosage if appropriate. Moderate Monitor patients for signs of urinary retention or reduced gastric motility when oxycodone is used concomitantly with an anticholinergic drug, such as tolterodine. Moderate Concomitant use of oxycodone with verapamil may increase oxycodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death.
Discontinuation of verapamil could decrease oxycodone plasma concentrations, decrease opioid efficacy, and potentially lead to a withdrawal syndrome in those with physical dependence to oxycodone. If verapamil is discontinued, monitor the patient carefully and consider increasing the opioid dosage if appropriate.
Moderate Concomitant use of oxycodone with other CNS depressants, such as trazodone, can lead to additive respiratory depression, hypotension, profound sedation, or coma.
Moderate The concurrent use of trimethobenzamide with other medications that cause CNS depression, like opiate agonists, may potentiate the effects of either trimethobenzamide or the opiate agonist. Moderate Monitor patients for signs of urinary retention or reduced gastric motility when trospium, an anticholinergic drug for overactive bladder. Moderate Any substances that act on the CNS may theoretically interact with valerian, Valeriana officinalis.
The valerian derivative, dihydrovaltrate, binds at barbiturate binding sites; valerenic acid has been shown to inhibit enzyme-induced breakdown of GABA in the brain; the non-volatile monoterpenes valepotriates have sedative activity. The sedative effect may be additive to other drugs with sedative actions, such as the opiate agonists. If valerian is used concurrently with a CNS depressant, a reduced dosage of the CNS depressant may be required, or, the valerian supplement may be discontinued.
Moderate Concomitant use of vemurafenib and oxycodone may result in altered concentrations of oxycodone. Use caution and monitor patients for toxicity and efficacy.
Moderate Vigabatrin may cause somnolence and fatigue. Abuse of oxycodone hydrochloride tablets poses a risk of overdose and death. The risk is increased with concurrent abuse of alcohol and other substances. Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV. Psychic dependence, physical dependence and tolerance may develop upon repeated administration of this drug.
The adverse effects of narcotics may be markedly exaggerated in the presence of head injury, intracranial lesions or a pre-existing increase in intracranial pressure. Narcotics may obscure the clinical course of patients with head injuries or acute abdominal conditions. Use of oxycodone hydrochloride tablets is associated with increased potential risks and should be used only with caution in the following conditions: Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed oxycodone hydrochloride tablets.
Addiction can occur at recommended dosages and if the drug is misused or abused. Risks are increased in patients with a personal or family history of substance abuse including drug or alcohol abuse or addiction or mental illness e.
The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as oxycodone hydrochloride tablets, but use in such patients necessitates intensive counseling about the risks and proper use of oxycodone hydrochloride tablets along with intensive monitoring for signs of addiction, abuse, and misuse. Opioids are sought by drug abusers and people with addiction disorders and are subject to criminal diversion.
Consider these risks when prescribing or dispensing oxycodone hydrochloride tablets. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the proper disposal of unused drugs [see Patient Counseling Information 17 ]. Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Carbon dioxide CO2 retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.
While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of oxycodone hydrochloride tablets, the risk is greatest during the initiation of therapy or following a dosage increase. Monitor patients closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy with and following dosage increases of oxycodone hydrochloride tablets.
To reduce the risk of respiratory depression, proper dosing and titration of oxycodone hydrochloride tablets are essential [see Dosage and Administration 2 ]. Overestimating the oxycodone hydrochloride tablets dosage when converting patients from another opioid product can result in fatal overdose with the first dose. Accidental ingestion of even one dose of oxycodone hydrochloride tablets, especially by children, can result in respiratory depression and death due to an overdose of oxycodone.
Neonatal Opioid Withdrawal Syndrome Prolonged use of oxycodone hydrochloride tablets during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts.
Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for a prolonged period of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Use in Specific Populations 8. Similarly, discontinuation of a CYP3A4 inducer, such as rifampin, carbamazepine, and phenytoin, in oxycodone-treated patients may increase oxycodone plasma concentrations and prolong opioid adverse reactions.
When using oxycodone hydrochloride tablets with CYP3A4 inhibitors or discontinuing CYP3A4 inducers in oxycodone-treated patients, monitor patients closely at frequent intervals and consider dosage reduction of oxycodone hydrochloride tablets until stable drugs effects are achieved [see Drug Interactions 7 ]. Concomitant use of oxycodone hydrochloride tablets with CYP3A4 inducers or discontinuation of a CYP3A4 inhibitor could decrease oxycodone plasma concentrations, decrease opioid efficacy or, possibly, lead to a withdrawal syndrome in a patient who had developed physical dependence to oxycodone.
When using oxycodone hydrochloride tablets with CYP3A4 inducers or discontinuing CYP3A4 inhibitors, monitor patients closely at frequent intervals and consider increasing the opioid dosage if needed to maintain adequate analgesia or if symptoms of opioid withdrawal occur [see Drug Interactions 7 ]. Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Profound sedation, respiratory depression, coma, and death may result from the concomitant use of oxycodone hydrochloride tablets with benzodiazepines or other CNS depressants e.
Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone.
Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics [see Drug Interactions 7 ]. If the decision is made to prescribe a benzodiazepine or other CNS depressant concomitantly with an opioid analgesic, prescribe the lowest effective dosages and minimum durations of concomitant use.
In patients already receiving an opioid analgesic, prescribe a lower initial dose of the benzodiazepine or other CNS depressant than indicated in the absence of an opioid, and titrate based on clinical response. If an opioid analgesic is initiated in a patient already taking a benzodiazepine or other CNS depressant, prescribe a lower initial dose of the opioid analgesic, and titrate based on clinical response.
Follow patients closely for signs and symptoms of respiratory depression and sedation. Advise both patients and caregivers about the risks of respiratory depression and sedation when oxycodone hydrochloride tablets are used with benzodiazepines or other CNS depressants including alcohol and illicit drugs. Advise patients not to drive or operate dangerous machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined.
Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs [see Drug Interactions 7 , Patient Counseling Information 17 ].
© Copyright 2017 Oxycodone hcl 20mg tab *** Canadian Drugstore.